Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Gains from Investment Securities (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Gains from Investment Securities for 6 consecutive years, with -$57000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$57000.0, compared with a TTM value of -$1.8 million through Dec 2025, down 117.43%, and an annual FY2025 reading of -$140000.0, changed N/A over the prior year.
  • Gains from Investment Securities was -$57000.0 for Q4 2025 at Avidity Biosciences, up from -$1.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $12.1 million in Q4 2021 and bottomed at -$1.7 million in Q4 2023.
  • Average Gains from Investment Securities over 4 years is $2.4 million, with a median of $118000.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities rose 25.33% in 2021, then soared 9087.23% in 2022.
  • Year by year, Gains from Investment Securities stood at $12.1 million in 2021, then plummeted by 96.33% to $443000.0 in 2022, then crashed by 493.0% to -$1.7 million in 2023, then skyrocketed by 96.73% to -$57000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for RNA at -$57000.0 in Q4 2025, -$1.7 million in Q4 2023, and $443000.0 in Q3 2022.